Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 12:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 843 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo equivalent Clear all

Conditions: Asthma
Interventions: Beclomethasone dipropionate BAI, Placebo BAI, albuterol/salbutamol 90 mcg, Beclomethasone dipropionate MDI, Placebo MDI; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 628 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 75
States / cities: Hoover, Alabama • Montgomery, Alabama • Phoenix, Arizona + 62 more

Conditions: Myasthenia Gravis, Generalized
Interventions: Amifampridine Phosphate, Placebo Oral Tablet; Drug
Lead sponsor: Catalyst Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Cleveland, Ohio • Philadelphia, Pennsylvania

Conditions: Womens Health, Menstrual Symptoms
Interventions: Effera® (human equivalent lactoferrin), Placebo; Dietary Supplement · Other
Lead sponsor: Helaina Inc.; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: San Francisco, California

Conditions: Crohn's Disease
Interventions: Vedolizumab, placebo; Drug
Lead sponsor: Marc Schwartz; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pain
Interventions: Ibuprofen Sodium, Standard Ibuprofen, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: COVID-19
Interventions: Placebo, Remdesivir, Risankizumab; Other · Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 32
States / cities: Tucson, Arizona • Bakersfield, California • Newport Beach, California + 26 more

Conditions: Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
Interventions: SGN-40, placebo, rituximab, etoposide, carboplatin, ifosfamide; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 24
States / cities: Birmingham, Alabama • Los Angeles, California • Stanford, California + 21 more

Conditions: Cannabis, Psychotic Disorders
Interventions: THC, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 35 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Churg-Strauss Syndrome, Eosinophilic Granulomatosis With Polyangiitis
Interventions: Mepolizumab, Prednisolone; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 14
States / cities: Denver, Colorado • Bethesda, Maryland • Boston, Massachusetts + 10 more

Conditions: Anterior Cruciate Ligament (ACL) Reconstruction
Interventions: Gabapentin; Other
Lead sponsor: Children's Healthcare of Atlanta; Other
Eligibility: 12 Years to 18 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Chronic Lung Disease, Bronchopulmonary Dysplasia
Interventions: Spironolactone, Placebo; Drug
Lead sponsor: West Virginia University Healthcare; Other
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Systemic Sclerosis-Associated PAH
Interventions: Rituximab, Placebo, CMRI, prednisone, methylprednisolone, diphenhydramine, acetaminophen; Biological · Other · Diagnostic Test + 1 more
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 17
States / cities: Stanford, California • Aurora, Colorado • Iowa City, Iowa + 13 more

Conditions: Anemia, Sickle Cell
Interventions: Arginine, Placebo; Drug
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 5 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 17
States / cities: Oakland, California • San Francisco, California • Denver, Colorado + 10 more

Conditions: Major Depressive Disorder
Interventions: LY2216684, Placebo, Escitalopram; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 469 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 4
States / cities: Orlando, Florida • Prairie Village, Kansas • Allentown, Pennsylvania + 1 more

Conditions: Carpal Tunnel Surgery, Trigger Finger Disorder, De Quervain Syndrome, Guyon's Canal, Dupuytren Contracture, Morton Neuroma, Tarsal Tunnel Syndrome, Plantar Fasciopathy, Peroneal Nerve Entrapment
Interventions: NAC, NAC 0mg/day (Placebo); Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Chronic Pain
Interventions: Kindolor Tosylate, Placebo; Drug
Lead sponsor: Lohocla Research Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Body Dysmorphic Disorder
Interventions: Fluoxetine, Placebo; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: Up to 16 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 2
States / cities: The Bronx, New York • Providence, Rhode Island

Conditions: Obesity, Inflammation
Interventions: Grape powder, followed by placebo powder, Placebo powder followed by grape powder; Dietary Supplement
Lead sponsor: USDA, Western Human Nutrition Research Center; Federal
Eligibility: 20 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Davis, California

Conditions: Epilepsy
Interventions: Placebo, Brivaracetam; Other · Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 16 Years to 65 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 26
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Fresno, California + 23 more

Conditions: COPD
Interventions: roflumilast, placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 40 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Seizures, Lennox Gastaut Syndrome
Interventions: Carisbamate; Drug
Lead sponsor: SK Life Science, Inc.; Industry
Eligibility: 4 Years to 55 Years
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 22
States / cities: Palo Alto, California • Jacksonville, Florida • Orlando, Florida + 18 more

Conditions: Postoperative Pain Control in Surgical Neonates
Interventions: Ketorolac, placebo; Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 1 Week to 3 Months
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Spinal Cord Injury
Interventions: Exercise; Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Amyotrophic Lateral Sclerosis
Interventions: SLS-005, Matching Placebo; Drug
Lead sponsor: Merit E. Cudkowicz, MD; Other
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma

Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG

Effera Dose Response: Women's Health

Vedolizumab Post Op Study

Ibuprofen Sodium Tension Headache Study

ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL

Cannabinoids and Cerebellar-Motor Functioning

Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921

Gabapentin Premedication for ACL Reconstruction: RCT

Determining the Effect of Spironolactone on Electrolyte Supplementation in Preterm Infants With Chronic Lung Disease

Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

Effectiveness of Arginine as a Treatment for Sickle Cell Anemia

A Study for Participants With Major Depression

NAC-REPAIR for Post-surgical Pain

A Study to Test the Effects of Kindolor at Different Doses in Healthy Adults

Fluoxetine in Pediatric Body Dysmorphic Disorder

Anti-Inflammatory Activities of Grapes in Humans at Risk for Cardiovascular Disease

A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.

A Placebo-controlled Trial of Daliresp on Chronic Obstructive Pulmonary Disease (COPD)

Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

The Use of Ketorolac in Surgical Neonates

Effects of Exercise in People With Paraplegia

HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose